+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriatic Arthritis - Epidemiology Forecast to 2030

  • ID: 5387735
  • Drug Pipelines
  • July 2021
  • Region: Global
  • 90 pages
  • DelveInsight
This ‘Psoriatic Arthritis- Epidemiology Forecast - 2030' report delivers an in-depth understanding of the historical and forecasted epidemiology of Psoriatic Arthritis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Psoriatic Arthritis: Disease Understanding

Psoriatic Arthritis Overview

Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin, and nail disease characterized by red, scaly rashes, and thick pitted fingernails. The disease is similar to rheumatoid arthritis in symptoms, characterized by joint inflammation. However, psoriatic arthritis tends to affect fewer joints than rheumatoid arthritis and does not produce the typical rheumatoid arthritis antibodies.

Arthritis associated with psoriasis was first described in 1956 by Wright. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis - a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of PsA remained poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

The etiology and pathogenesis of PsA involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of psoriatic arthritis patients have at least one first-degree relative who also has psoriasis or PsA. Genes associated with PsA include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression and signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma is known to induce flares of psoriatic skin lesions known as the Koebner phenomenon. There is evidence the joint trauma may induce a flare of arthritis, referred to as the “internal” or “deep” Koebner phenomenon.

PsA shares some clinical features with other inflammatory arthritides, including rheumatoid arthritis (RA), reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnose. Unlike PsA, RA tends to be symmetrical and generally spares the DIP joints. AS has an earlier age of onset compared to psoriatic arthritis, and sacroiliac involvement is usually symmetric rather than asymmetric.

There are no laboratory tests that are specific for PsA. Acute phase reactants such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) may become elevated as in most inflammatory diseases. However, a normal ESR and CRP should not be used to rule out a diagnosis of PsA as these levels increase in only about 40% of patients. Besides, imaging plays a central role. Classical radiography has been used for this purpose for over 100 years. It allows identifying the late stages of the disease when bone tissue is affected. In the last 20 years, many new imaging modalities, such as ultrasonography (US), computed tomography (CT), and magnetic resonance (MR), have been developed and became important diagnostic tools for the evaluation of rheumatoid diseases. They enable the assessment and monitoring of early inflammatory changes. As a result, patients have earlier access to modern treatment, and thus the formation of destructive changes in joints can be markedly delayed or even avoided.

PsA may range from mild to severe, and it is crucial to treat it no matter the severity. If left untreated, PsA can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating PsA may also help reduce inflammation in the body, leading to other diseases. These other diseases are often referred to as comorbidities. However, at present, no cure for PsA exists, so treatment goals are to slow disease progression, improve quality of life, lessen pain, and preserve the range of motion. In most patients with PsA, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs if a patient does not adequately respond.

Psoriatic Arthritis: Epidemiology

The Psoriatic Arthritis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent cases of Psoriatic Arthritis, Diagnosed cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, Age-specific cases of Psoriatic Arthritis and Severity-specific Prevalence of Psoriatic Arthritis. The report includes the prevalent scenario of Psoriatic Arthritis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Psoriatic Arthritis Epidemiology

The epidemiology segment also provides the Psoriatic Arthritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Psoriatic Arthritis in the 7MM countries was estimated to be 1,486,869 cases in 2020.

As per the estimates, the United States had the highest prevalent population of Psoriatic Arthritis in 2020. Among the EU5 countries, Spain had the highest prevalent population of Psoriatic Arthritis with 237,283 cases, followed by Italy in 2020. On the other hand, France had the lowest prevalent population of 52,882 cases in 2020.

Scope of the Report
  • Psoriatic Arthritis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • Psoriatic Arthritis Epidemiology Report and Model provide an overview of the risk factors and global trends of Psoriatic Arthritis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Psoriatic Arthritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Psoriatic Arthritis.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by total prevalent cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by diagnosed cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by gender-specific cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by age-specific cases of Psoriatic Arthritis in the 7MM.
  • The report provides the segmentation of the Psoriatic Arthritis epidemiology by the severity-specific prevalence of Psoriatic Arthritis in the 7MM.
Report Highlights
  • 10-year Forecast of Psoriatic Arthritis epidemiology
  • 7MM Coverage
  • Prevalent cases of Psoriatic Arthritis
  • Diagnosed Prevalent Cases of Psoriatic Arthritis
  • Gender-specific Cases of Psoriatic Arthritis
  • Age-specific Cases of Psoriatic Arthritis
  • Severity-specific Prevalence of Psoriatic Arthritis
KOL Views

The publisher interviews KOLs and obtain SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population pertaining to Psoriatic Arthritis?
  • What are the key findings pertaining to the Psoriatic Arthritis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?
  • What would be the total number of patients with Psoriatic Arthritis across the 7MM during the forecast period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
  • At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2018-2030)?
  • What are the disease risk, burdens, and unmet needs of Psoriatic Arthritis?
  • What are the currently available treatments for Psoriatic Arthritis?
Reasons to Buy

Psoriatic Arthritis Epidemiology report will allow the user to:
  • Develop business strategies by understanding the trends shaping and driving the global Psoriatic Arthritis market
  • Quantify patient populations in the global Psoriatic Arthritis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Psoriatic Arthritis therapeutics in each of the markets covered
  • Understand the magnitude of the Psoriatic Arthritis population by its prevalent cases.
  • Understand the magnitude of the Psoriatic Arthritis population by its diagnosed cases.
  • Understand the magnitude of the Psoriatic Arthritis population by its gender-specific cases.
  • Understand the magnitude of the Psoriatic Arthritis population by its age-specific cases.
  • Understand the magnitude of the Psoriatic Arthritis population by its severity-specific cases.
  • The Psoriatic Arthritis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Psoriatic Arthritis Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Estimates of the prevalence of PsA vary widely and are usually not determined by population-based studies. The first population-based studies were performed in Olmsted County, Minnesota, using the review of the medical records of the Rochester epidemiology project. The residents with any diagnosis consistent with psoriasis and/or PsA between January 1982 and December 1991 were analyzed. In the records of 1,844 patients diagnosed with psoriasis, 1,056 cases were confirmed by a dermatologist, in which 66 cases were diagnosed with PsA. The average age and sex-adjusted incidence rate per 100,000 US population were 6.59, and the prevalence was about 1/1000 in 1992. The average age at diagnosis was 40.7 years. At diagnosis, 91%, 3%, and 6% of cases had oligoarthritis, polyarthritis, and spondylitis, respectively
Note: Product cover images may vary from those shown
1. Key Insights

2. Report Introduction

3. Psoriatic Arthritis Market Overview at a Glance
3.1. Market Share (%) Distribution of Psoriatic Arthritis in 2018
3.2. Market Share (%) Distribution of Psoriatic Arthritis in 2030

4. Executive Summary of Psoriatic Arthritis

5. Disease Background and Overview
5.1. Introduction
5.2. Clinical Manifestations
5.3. Classification
5.4. Risk Factors
5.5. Pathogenesis of PSA
5.6. Diagnosis
5.7. Differential Diagnosis
5.8. Treatment and Management
5.8.1.ACR/NPF Recommendations for Psoriatic arthritis
5.8.2.Summary of differences in recommendations
5.8.3.EULAR Recommendations

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Population of Psoriatic arthritis (PsA)
6.3. Epidemiology of Psoriatic arthritis (PsA)
6.4. The United States
6.4.1.Prevalent Cases of Psoriatic arthritis (PsA) in the United States
6.4.2.Diagnosed Cases of Psoriatic arthritis (PsA) in the US
6.4.3.Age-specific Cases of Psoriatic Arthritis in the United States
6.4.4.Gender-specific cases of Psoriatic Arthritis in the United States
6.4.5.Severity-specific Prevalence of Psoriatic Arthritis in the United States
6.5. EU5
6.5.1.Germany
6.5.1.1. Prevalent Cases of Psoriatic arthritis (PsA) in Germany
6.5.1.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Germany
6.5.1.3. Age-specific Cases of Psoriatic Arthritis in Germany
6.5.1.4. Gender-specific cases of Psoriatic Arthritis in Germany
6.5.1.5. Severity-specific Prevalence of Psoriatic Arthritis in Germany
6.5.2.France
6.5.2.1. Prevalent Cases of Psoriatic arthritis (PsA) in France
6.5.2.2. Diagnosed Cases of Psoriatic arthritis (PsA) in France
6.5.2.3. Age-specific Cases of Psoriatic Arthritis in France
6.5.2.4. Gender-specific cases of Psoriatic Arthritis in France
6.5.2.5. Severity-specific Prevalence of Psoriatic Arthritis in France
6.5.3.Italy
6.5.3.1. Prevalent Cases of Psoriatic arthritis (PsA) in Italy
6.5.3.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Italy
6.5.3.3. Age-specific Cases of Psoriatic Arthritis in Italy
6.5.3.4. Gender-specific cases of Psoriatic Arthritis in Italy
6.5.3.5. Severity-specific Prevalence of Psoriatic Arthritis in Italy
6.5.4.Spain
6.5.4.1. Prevalent Cases of Psoriatic arthritis (PsA) in Spain
6.5.4.2. Diagnosed Cases of Psoriatic arthritis (PsA) in Spain
6.5.4.3. Age-specific Cases of Psoriatic Arthritis in Spain
6.5.4.4. Gender-specific cases of Psoriatic Arthritis in Spain
6.5.4.5. Severity-specific Prevalence of Psoriatic Arthritis in Spain
6.5.5.The United Kingdom
6.5.5.1. Prevalent Cases of Psoriatic arthritis (PsA) in the UK
6.5.5.2. Diagnosed Cases of Psoriatic arthritis (PsA) in the UK
6.5.5.3. Age-specific Cases of Psoriatic Arthritis in the UK
6.5.5.4. Gender-specific cases of Psoriatic Arthritis in the UK
6.5.5.5. Severity-specific Prevalence of Psoriatic Arthritis in the UK
6.6. Japan
6.6.1.Prevalent Cases of Psoriatic arthritis (PsA) in Japan
6.6.2.Diagnosed Cases of Psoriatic arthritis (PsA) in Japan
6.6.3.Age-specific Cases of Psoriatic Arthritis in Japan
6.6.4.Gender-specific cases of Psoriatic Arthritis in Japan
6.6.5.Severity-specific Prevalence of Psoriatic Arthritis in Japan

7. Organizations contributing towards Psoriatic arthritis (PsA)

8. Patient Journey

9. Case Reports

19. Appendix
19.1. Bibliography
19.2. Report Methodology

20. Publisher Capabilities

21. Disclaimer

22. About the Publisher

List of Tables
Table 1: Summary of Psoriatic Arthritis, Epidemiology, and Key Events (2018-2030)
Table 2: CASPAR criteria
Table 3: Moll and Wright Classification
Table 4: Operational definition of classification of psoriatic arthritis
Table 5: Suggested Diagnostic Algorithm
Table 6: Clinical characteristics of different types of arthritis that can aid differential diagnosis
Table 7: 2018 ACR/NPF Recommendations for the initial treatment for active psoriatic arthritis who are OSM‐ and other treatment naive
Table 8: 2018 ACR/NPF Recommendations for active PsA despite treatment with a TNFi biologics
Table 9: 2018 ACR/NPF Recommendations for active PsA despite treatment with an IL‐17i or an IL‐12/23i biologics
Table 10: 2018 ACR/NPF Recommendations for PsA including treat‐to‐target, active axial disease, enthesitis, or active inflammatory bowel disease
Table 11: 2018 ACR/NPF Recommendations for PsA and comorbidities, including concomitant diabetes and recurrent-serious infections
Table 12: 2018 ACR/NPF Recommendations for nonpharmacologic interventions in patients with active PsA regardless of pharmacologic treatment status
Table 13: Summary of differences in recommendations
Table 14: 2019 EULAR recommendations for the pharmacological management of psoriatic arthritis
Table 15: Prevalent Population of Psoriatic arthritis in 7MM (2018-2030)
Table 16: Prevalent Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Table 17: Diagnosed Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Table 18: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Table 19: Gender-specific cases of Psoriatic Arthritis in the United States (2018-2030)
Table 20: Severity-specific Prevalence of Psoriatic Arthritis in the United States (2018-2030)
Table 21: Prevalent Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Table 22: Diagnosed Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Table 23: Age-specific Cases of Psoriatic Arthritis in Germany (2018-2030)
Table 24: Gender-specific cases of Psoriatic Arthritis in Germany (2018-2030)
Table 25: Severity-specific Prevalence of Psoriatic Arthritis in Germany (2018-2030)
Table 26: Prevalent Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Table 27: Diagnosed Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Table 28: Age-specific Cases of Psoriatic Arthritis in France (2018-2030)
Table 29: Gender-specific cases of Psoriatic Arthritis in France (2018-2030)
Table 30: Severity-specific Prevalence of Psoriatic Arthritis in France (2018-2030)
Table 31: Prevalent Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Table 32: Diagnosed Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Table 33: Age-specific Cases of Psoriatic Arthritis in Italy (2018-2030)
Table 34: Gender-specific cases of Psoriatic Arthritis in Italy (2018-2030)
Table 35: Severity-specific Prevalence of Psoriatic Arthritis in Italy (2018-2030)
Table 36: Prevalent Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Table 37: Diagnosed Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Table 38: Age-specific Cases of Psoriatic Arthritis in Spain (2018-2030)
Table 39: Gender-specific cases of Psoriatic Arthritis in Spain (2018-2030)
Table 40: Severity-specific Prevalence of Psoriatic Arthritis in Spain (2018-2030)
Table 41: Prevalent Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Table 42: Diagnosed Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Table 43: Age-specific Cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 44: Gender-specific cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 45: Severity-specific Prevalence of Psoriatic Arthritis in the United Kingdom (2018-2030)
Table 46: Prevalent Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Table 47: Diagnosed Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Table 48: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Table 49: Gender-specific cases of Psoriatic Arthritis in Japan (2018-2030)
Table 50: Severity-specific Prevalence of Psoriatic Arthritis in Japan (2018-2030)

List of Figures
Figure 1: Clinical Presentations
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Key cell types and secretion of key inflammatory mediators in psoriatic arthritis
Figure 5: Adaptive and innate immune cells and activated pathways in psoriatic arthritis
Figure 6: Diagnosis of PsA
Figure 7: Differential Diagnosis
Figure 8: Pharmacologic, non-pharmacologic, and symptomatic therapies for psoriatic arthritis
Figure 9: The EULAR 2019 algorithm for treatment of PsA with pharmacological non-topical treatments
Figure 10: Psoriatic Arthritis Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 11: Total Prevalent Population of Psoriatic arthritis (PsA) in 7MM (2018-2030)
Figure 12: Prevalent Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Figure 13: Diagnosed Cases of Psoriatic arthritis (PsA) in the United States (2018-2030)
Figure 14: Age-specific Cases of Psoriatic Arthritis in the United States (2018-2030)
Figure 15: Gender-specific cases of Psoriatic Arthritis in the United States (2018-2030)
Figure 16: Severity-specific Prevalence of Psoriatic Arthritis in the United States (2018-2030)
Figure 17: Prevalent Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Figure 18: Diagnosed Cases of Psoriatic arthritis (PsA) in Germany (2018-2030)
Figure 19: Age-specific Cases of Psoriatic Arthritis in Germany (2018-2030)
Figure 20: Gender-specific cases of Psoriatic Arthritis in Germany (2018-2030)
Figure 21: Severity-specific Prevalence of Psoriatic Arthritis in Germany (2018-2030)
Figure 22: Prevalent Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Figure 23: Diagnosed Cases of Psoriatic arthritis (PsA) in France (2018-2030)
Figure 24: Age-specific Cases of Psoriatic Arthritis in France (2018-2030)
Figure 25: Gender-specific cases of Psoriatic Arthritis in France (2018-2030)
Figure 26: Severity-specific Prevalence of Psoriatic Arthritis in France (2018-2030)
Figure 27: Prevalent Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Figure 28: Diagnosed Cases of Psoriatic arthritis (PsA) in Italy (2018-2030)
Figure 29: Age-specific Cases of Psoriatic Arthritis in Italy (2018-2030)
Figure 30: Gender-specific cases of Psoriatic Arthritis in Italy (2018-2030)
Figure 31: Severity-specific Prevalence of Psoriatic Arthritis in Italy (2018-2030)
Figure 32: Prevalent Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Figure 33: Diagnosed Cases of Psoriatic arthritis (PsA) in Spain (2018-2030)
Figure 34: Age-specific Cases of Psoriatic Arthritis in Spain (2018-2030)
Figure 35: Gender-specific cases of Psoriatic Arthritis in Spain (2018-2030)
Figure 36: Severity-specific Prevalence of Psoriatic Arthritis in Spain (2018-2030)
Figure 37: Prevalent Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Figure 38: Diagnosed Cases of Psoriatic arthritis (PsA) in the United Kingdom (2018-2030)
Figure 39: Age-specific Cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 40: Gender-specific cases of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 41: Severity-specific Prevalence of Psoriatic Arthritis in the United Kingdom (2018-2030)
Figure 42: Prevalent Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Figure 43: Diagnosed Cases of Psoriatic arthritis (PsA) in Japan (2018-2030)
Figure 44: Age-specific Cases of Psoriatic Arthritis in Japan (2018-2030)
Figure 45: Gender-specific cases of Psoriatic Arthritis Japan (2018-2030)
Figure 46: Severity-specific Prevalence of Psoriatic Arthritis in Japan (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll